JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report

JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value : final evidence report

Collection:
Health Policy and Services Research
Author(s):
Atlas, Steven J., author
Fox, Grace E., author
Agboola, Foluso, author
Campbell, Jonathan D., author
Pearson, Steven D., author
Rind, David M., author
Brouwer, Elizabeth, author
Carlson, Josh, author
Chen, Yilin, (Of University of Washington), author
Hansen, Ryan N., author
Contributor(s):
Institute for Clinical and Economic Review, issuing body.
New England Comparative Effectiveness Public Advisory Council, issuing body.
Publication:
[Boston, Massachusetts] : Institute for Clinical and Economic Review, February 27, 2023
Language(s):
English
Format:
Text
Subject(s):
Antibodies, Monoclonal -- therapeutic use
Dermatitis, Atopic
Janus Kinase Inhibitors -- therapeutic use
United States
Genre(s):
Technical Report
Abstract:
We compared the cost and effectiveness of abrocitinib, baricitinib, tralokinumab and upadacitinib for moderate to severe atopic dermatitis to topical emollients (standard of care) and dupilumab, over a five-year time horizon taking a health system perspective.
Copyright:
Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
Extent:
1 online resource (1 PDF file (338 pages))
Illustrations:
Illustrations
NLM Unique ID:
9918697384806676 (See catalog record)
Permanent Link:
http://resource.nlm.nih.gov/9918697384806676